ScoreWhy is Neurocrine Biosciences, Inc. ?
1
High Management Efficiency with a high ROE of 20.73%
2
The company is Net-Debt Free
3
Healthy long term growth as Net Sales has grown by an annual rate of 22.29% and Operating profit at 14.21%
4
With a growth in Net Profit of 2405.06%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- PRE-TAX PROFIT(Q) At USD 242.7 MM has Grown at 434.58%
- OPERATING CASH FLOW(Y) Highest at USD 863.7 MM
- ROCE(HY) Highest at 22.5%
5
With ROE of 14.97%, it has a very attractive valuation with a 3.96 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 31.42%, its profits have risen by 26.4% ; the PEG ratio of the company is 0.9
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Neurocrine Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Neurocrine Biosciences, Inc. for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Neurocrine Biosciences, Inc.
31.42%
0.72
31.61%
S&P 500
22.99%
1.78
12.93%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
22.29%
EBIT Growth (5y)
14.21%
EBIT to Interest (avg)
16.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.85
Tax Ratio
34.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
30.41%
ROE (avg)
20.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
3.96
EV to EBIT
18.00
EV to EBITDA
17.18
EV to Capital Employed
6.26
EV to Sales
4.00
PEG Ratio
0.93
Dividend Yield
NA
ROCE (Latest)
34.81%
ROE (Latest)
14.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
PRE-TAX PROFIT(Q)
At USD 242.7 MM has Grown at 434.58%
OPERATING CASH FLOW(Y)
Highest at USD 863.7 MM
ROCE(HY)
Highest at 22.5%
NET SALES(Q)
Highest at USD 814.5 MM
RAW MATERIAL COST(Y)
Fallen by 0.08% (YoY
CASH AND EQV(HY)
Highest at USD 2,796.6 MM
NET PROFIT(Q)
Highest at USD 194.61 MM
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Neurocrine Biosciences, Inc.
Pre-Tax Profit
At USD 242.7 MM has Grown at 434.58%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 194.61 MM has Grown at 697.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 814.5 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 863.7 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 814.5 MM has Grown at 42.25%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Profit
Highest at USD 194.61 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 2,796.6 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by 0.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
